ArticleJournal of virology2008
Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells.
Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01289496 (Ribavirin Dose Optimization for the Treatment of Hepatitis C), which is not on this map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ribavirin Dose Optimization for the Treatment of Hepatitis C: A Pilot Study
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- Transcriptional insights into the CD8Journal of translational medicine · 2020Pooled it
- HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.World journal of gastroenterology · 2014Trial
- Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C.PLoS pathogens · 2013Trial
- The development of a pan-genotypic T cell vaccine against hepatitis C virus using heterologous prime-boost strategies.Hepatology (Baltimore, Md.) · 2026Article
- Functional Antigen-Specific CD8 TEuropean journal of immunology · 2025Article
- Review
- Immunomodulatory Role of Interferons in Viral and Bacterial Infections.International journal of molecular sciences · 2023Review
- Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products.Frontiers in immunology · 2022Article
- In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?World journal of hepatology · 2021Review
- Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV.Viruses · 2021Review
- SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses.Future microbiology · 2021Review
- Expansion of Unique Hepatitis C Virus-Specific Public CD8Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection.Frontiers in immunology · 2021Review
- Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.Archives of virology · 2020Article
- Enhanced T Cell Responses Induced by a Necrotic Dendritic Cell Vaccine, Expressing HCV NS3.Frontiers in microbiology · 2020Article
- Review
- Review
- Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.Journal of virology · 2019Article
- Viruses Teaching Immunology: Role of LCMV Model and Human Viral Infections in Immunological Discoveries.Viruses · 2019Review
- Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus.Hepatology communications · 2018Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of acute hepatitis C virus (HCV) infections progress to chronicity and progressive liver damage. Alpha interferon (IFN-alpha) antiviral therapy achieves the highest rate of success when IFN-alpha is administered early during the acute phase, but the underlying mechanisms are unknown. We used a panel of major histocompatibility complex class I tetramers to monitor the phenotypic and functional signatures of HCV-specific T cells during acute HCV infection with different infection outcomes and during early IFN therapy. We demonstrate that spontaneous resolution correlates with the early development of polyfunctional (IFN-gamma- and IL-2-producing and CD107a(+)) virus-specific CD8(+) T cells. These polyfunctional T cells are distinguished by the expression of CD127 and Bcl-2 and represent a transitional memory T-cell subset that exhibits the phenotypic and functional signatures of both central and effector memory T cells. In contrast, HCV-specific CD8(+) T cells in acute infections evolving to chronicity expressed low levels of CD127 and Bcl-2, exhibited diminished proliferation and cytokine production, and eventually disappeared from the periphery. Early therapeutic intervention with pegylated IFN-alpha rescued polyfunctional memory T cells expressing high levels of CD127 and Bcl-2. These cells were detectable for up to 1 year following discontinuation of therapy. Our results suggest that the polyfunctionality of HCV-specific T cells can be predictive of the outcome of acute HCV infection and that early therapeutic intervention can reconstitute the pool of long-lived polyfunctional memory T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.